MA53541A - Dérivés hétéroaryles bicycliques - Google Patents

Dérivés hétéroaryles bicycliques

Info

Publication number
MA53541A
MA53541A MA053541A MA53541A MA53541A MA 53541 A MA53541 A MA 53541A MA 053541 A MA053541 A MA 053541A MA 53541 A MA53541 A MA 53541A MA 53541 A MA53541 A MA 53541A
Authority
MA
Morocco
Prior art keywords
bicyclic derivatives
heteroaryl bicyclic
heteroaryl
derivatives
bicyclic
Prior art date
Application number
MA053541A
Other languages
English (en)
Other versions
MA53541B1 (fr
Inventor
Jennifer Louise Carter
Hasane Ratni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA53541A publication Critical patent/MA53541A/fr
Publication of MA53541B1 publication Critical patent/MA53541B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA53541A 2018-09-03 2019-09-02 Dérivés hétéroaryles bicycliques MA53541B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18192219 2018-09-03
PCT/EP2019/073303 WO2020048904A1 (fr) 2018-09-03 2019-09-02 Dérivés hétéroaryles bicycliques

Publications (2)

Publication Number Publication Date
MA53541A true MA53541A (fr) 2021-12-08
MA53541B1 MA53541B1 (fr) 2024-02-29

Family

ID=63490310

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53541A MA53541B1 (fr) 2018-09-03 2019-09-02 Dérivés hétéroaryles bicycliques

Country Status (33)

Country Link
US (1) US12084461B2 (fr)
EP (1) EP3846903B1 (fr)
JP (1) JP7398435B2 (fr)
KR (1) KR102829709B1 (fr)
CN (1) CN112566696B (fr)
AR (1) AR116051A1 (fr)
AU (1) AU2019336492B2 (fr)
BR (1) BR112021002170A2 (fr)
CA (1) CA3107593A1 (fr)
CL (1) CL2021000486A1 (fr)
CO (1) CO2021002415A2 (fr)
CR (1) CR20210104A (fr)
DK (1) DK3846903T3 (fr)
ES (1) ES2966947T3 (fr)
FI (1) FI3846903T3 (fr)
HR (1) HRP20231663T1 (fr)
HU (1) HUE064554T2 (fr)
IL (1) IL281175B2 (fr)
LT (1) LT3846903T (fr)
MA (1) MA53541B1 (fr)
MX (1) MX2021002087A (fr)
MY (1) MY208133A (fr)
PE (1) PE20210860A1 (fr)
PH (1) PH12021550320A1 (fr)
PL (1) PL3846903T3 (fr)
PT (1) PT3846903T (fr)
RS (1) RS64950B1 (fr)
SG (1) SG11202102137SA (fr)
SI (1) SI3846903T1 (fr)
TW (1) TWI841592B (fr)
UA (1) UA128482C2 (fr)
WO (1) WO2020048904A1 (fr)
ZA (1) ZA202007831B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12275709B2 (en) 2018-12-27 2025-04-15 Hoffmann-La Roche Inc. Process for the preparation of exo-tert-butyl N-(3-azabicyclo[3.2.1]octan-8-yl)carbamate

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994349A (en) 1997-10-27 1999-11-30 Howard University 3-carboalkoxy-2, 3-dihydro-1H-phenothiazin-4[10H]-one derivatives
DK1087934T3 (da) 1998-04-01 2004-06-28 Cardiome Pharma Corp Aminocyclohexyletherforbindelser og anvendelser deraf
WO2000047547A2 (fr) 1999-02-12 2000-08-17 Nortran Pharmaceuticals Inc. Composes d'amines cycloalkyles et utilisation de ceux-ci
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
WO2000071528A1 (fr) 1999-05-25 2000-11-30 Neurogen Corporation 4h-1,4-benzothiazine-2-carboxamides et leur utilisation en tant que ligands des recepteurs cerebraux gaba
WO2001032170A1 (fr) 1999-09-13 2001-05-10 Swope David M Composition et procede pour la reduction de la symptomatologie neurologique
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
WO2007032009A2 (fr) 2005-09-15 2007-03-22 Biomas Ltd. Utilisation de composes tellures pour le traitement du carcinome basocellulaire et/ou de la keratose actinique
KR101138045B1 (ko) 2007-05-11 2012-04-24 에프. 호프만-라 로슈 아게 아밀로이드 베타에 대한 조절제로서의 헤트아릴아닐린
WO2009052126A1 (fr) 2007-10-19 2009-04-23 Janssen Pharmaceutica, N.V. Modulateur de pipéridinyl et de pipérazinyl de la γ-secrétase
MX2011005046A (es) 2008-11-13 2011-06-01 Schering Corp Moduladores de gamma secretasa.
CA2753696A1 (fr) 2009-02-26 2010-09-02 Noritaka Kitazawa Composes heterocycliques condenses contenant de l'azote et leur utilisation en tant qu'inhibiteurs de production de la beta-amyloide
WO2010138901A1 (fr) * 2009-05-29 2010-12-02 Biogen Idec Ma Inc Composés contenant de l'acide carboxylique, leurs dérivés et procédés d'utilisation associés
WO2011028208A1 (fr) 2009-09-04 2011-03-10 Hewlett-Packard Development Company, L.P. Memristances basées sur des composés métalliques à valence mixte
WO2011007756A1 (fr) * 2009-07-13 2011-01-20 武田薬品工業株式会社 Composé hétérocyclique et son utilisation
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
WO2014060112A1 (fr) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines utiles en tant qu'inhibiteurs de kinases
EP3347363B1 (fr) 2015-09-09 2020-01-01 H. Hoffnabb-La Roche Ag Dérivés de n-(3-azabicyclo[3.2.1]octan-8-yl)-8-(4-phényl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[l,5-a]pyridin-2-amine en tant que modulateurs de gamma-secretase pour le traitement de la maladie d'alzheimer
WO2017097728A1 (fr) 2015-12-10 2017-06-15 F. Hoffmann-La Roche Ag Dérivés de pipéridine pontés
CN109311878B (zh) 2016-06-27 2022-05-24 豪夫迈·罗氏有限公司 作为γ-分泌酶调节剂的三唑并吡啶类化合物
AR109829A1 (es) 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
EP3535266B1 (fr) * 2016-11-01 2021-12-29 F. Hoffmann-La Roche AG Dérivés hétéroaryle bicycliques
AR110122A1 (es) 2016-11-08 2019-02-27 Hoffmann La Roche Fenoxitriazoles
WO2018111926A2 (fr) 2016-12-16 2018-06-21 Inception 3, Inc. Méthodes de traitement de la synaptopathie cochléaire
CN111417636B (zh) 2018-01-22 2023-09-26 豪夫迈·罗氏有限公司 三唑并-氮杂䓬衍生物

Also Published As

Publication number Publication date
AR116051A1 (es) 2021-03-25
IL281175A (en) 2021-04-29
LT3846903T (lt) 2024-01-10
CO2021002415A2 (es) 2021-03-08
KR102829709B1 (ko) 2025-07-04
SI3846903T1 (sl) 2024-02-29
PT3846903T (pt) 2023-12-14
US12084461B2 (en) 2024-09-10
IL281175B2 (en) 2024-01-01
WO2020048904A1 (fr) 2020-03-12
EP3846903B1 (fr) 2023-10-25
US20210323980A1 (en) 2021-10-21
FI3846903T3 (fi) 2023-12-19
RS64950B1 (sr) 2024-01-31
AU2019336492B2 (en) 2024-10-31
AU2019336492A1 (en) 2021-01-07
CN112566696B (zh) 2024-01-16
CL2021000486A1 (es) 2021-07-30
HRP20231663T1 (hr) 2024-03-15
CA3107593A1 (fr) 2020-03-12
TWI841592B (zh) 2024-05-11
MA53541B1 (fr) 2024-02-29
KR20210054515A (ko) 2021-05-13
ZA202007831B (en) 2026-03-25
PE20210860A1 (es) 2021-05-18
PL3846903T3 (pl) 2024-05-06
MX2021002087A (es) 2021-04-28
CN112566696A (zh) 2021-03-26
ES2966947T3 (es) 2024-04-25
JP2021535178A (ja) 2021-12-16
JP7398435B2 (ja) 2023-12-14
CR20210104A (es) 2021-04-19
UA128482C2 (uk) 2024-07-24
HUE064554T2 (hu) 2024-03-28
TW202023649A (zh) 2020-07-01
PH12021550320A1 (en) 2021-10-04
MY208133A (en) 2025-04-17
IL281175B1 (en) 2023-09-01
SG11202102137SA (en) 2021-04-29
EP3846903A1 (fr) 2021-07-14
BR112021002170A2 (pt) 2021-05-04
DK3846903T3 (da) 2024-01-02

Similar Documents

Publication Publication Date Title
PT3958977T (pt) Derivados de camptotecina
DK3956033T3 (da) Bicykliske forbindelser
PL3897842T3 (pl) Pochodne bicykliczne
DK3728252T3 (da) 4-azaindolforbindelser
PT3687999T (pt) Derivados de rapamicina
MA41898A (fr) Dérivés de quinazolinone bicyclique
LT3830085T (lt) Deuterinti lanifibranoro dariniai
EP4013751C0 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
EP3457851A4 (fr) Dérivés de sobétirome
EP3654987A4 (fr) Utilisation de dérivés aminoalkylbenzothiazépine
DK3768669T3 (da) Piperazinazaspiroderivater
EP4077334C0 (fr) Dérivés furoindazole
EP4021904C0 (fr) Dérivés d'alpha-d-galactopyranoside
PL3898637T3 (pl) Pochodne rapamycyny
EP3884940A4 (fr) Nouveau dérivé d'imidazole
EP3617195A4 (fr) Nouveaux dérivés de tétrahydronaphtyle urée
EP3885347A4 (fr) Dérivé de dihydropyrrolopyrazole
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
EP3554637A4 (fr) Dérivés de spiropipéridine
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
PT3796975T (pt) Derivados de sulfonilaminobenzamida
EP3400220A4 (fr) Dérivés de pyrazole
MA56504A (fr) Dérivés de pyridin-3-yle
DK3894410T3 (da) Substituerede xanthinderivater
EP3472151A4 (fr) Dérivés de prolinamide carbocycliques